BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mossenta M, Busato D, Baboci L, Cintio FD, Toffoli G, Bo MD. New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1086. [PMID: 31370258 DOI: 10.3390/cancers11081086] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wu CH, Hsu FT, Chao TL, Lee YH, Kuo YC. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo. Biomed Pharmacother 2022;145:112437. [PMID: 34864311 DOI: 10.1016/j.biopha.2021.112437] [Reference Citation Analysis]
4 Oh H, Lee JH. Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Ann Transl Med 2020;8:1530. [PMID: 33313275 DOI: 10.21037/atm-20-3526] [Reference Citation Analysis]
5 Han X, Yang J, Zeng F, Weng J, Zhang Y, Peng Q, Shen L, Ding S, Liu K, Gao Y. Programmable Synthetic Protein Circuits for the Identification and Suppression of Hepatocellular Carcinoma. Mol Ther Oncolytics 2020;17:70-82. [PMID: 32322664 DOI: 10.1016/j.omto.2020.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. J Hepatol. 2020;72:342-352. [PMID: 31954496 DOI: 10.1016/j.jhep.2019.09.010] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 90.0] [Reference Citation Analysis]
7 Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, Nedaeinia R, Haghjooy Javanmard S, Taherian M, Ahmadlou M, Salehi R, Sadeghi B, Manian M. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int 2021;21:62. [PMID: 33472628 DOI: 10.1186/s12935-020-01719-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
8 Taskaeva YS, Makarova VV, Gogaeva IS, Bgatova NP. Morphological Analysis of Blood Capillaries and Transport Function of Endothelial Cells in Hepatocellular Carcinoma-29. Bull Exp Biol Med 2020;169:276-80. [PMID: 32651829 DOI: 10.1007/s10517-020-04867-w] [Reference Citation Analysis]
9 Jeng KS, Sheen IS, Lin SS, Leu CM, Chang CF. The Role of Endoglin in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3208. [PMID: 33809908 DOI: 10.3390/ijms22063208] [Reference Citation Analysis]
10 Catalano A, Iacopetta D, Sinicropi MS, Franchini C. Diarylureas as Antitumor Agents. Applied Sciences 2021;11:374. [DOI: 10.3390/app11010374] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 10.0] [Reference Citation Analysis]
11 Taskaeva I, Bgatova N. Microvasculature in hepatocellular carcinoma: An ultrastructural study. Microvasc Res 2021;133:104094. [PMID: 33011171 DOI: 10.1016/j.mvr.2020.104094] [Reference Citation Analysis]
12 Fan Z, Zheng W, Li H, Wu W, Liu X, Sun Z, Hu H, Du L, Jia Q, Liu Q. LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells. Oncol Rep 2020;43:1641-9. [PMID: 32323822 DOI: 10.3892/or.2020.7541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yen CC, Yen CJ. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf 2021;:1-10. [PMID: 34668832 DOI: 10.1080/14740338.2022.1995353] [Reference Citation Analysis]
14 Chin Lim JT, Kwang LG, Wei Ho NC, Min Toh CC, Hua Too NS, Hooi L, Benoukraf T, Kah-hoe Chow P, Dan YY, Kai-hua Chow E, Toh TB, Shan Fong EL. Hepatocellular carcinoma organoid Co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121527] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Xie JY, Wei JX, Lv LH, Han QF, Yang WB, Li GL, Wang PX, Wu SB, Duan JX, Zhuo WF, Liu PQ, Min J. Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma. Cell Commun Signal 2020;18:46. [PMID: 32183816 DOI: 10.1186/s12964-020-00535-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
16 Sbenati RM, Zaraei SO, El-Gamal MI, Anbar HS, Tarazi H, Zoghbor MM, Mohamood NA, Khakpour MM, Zaher DM, Omar HA, Alach NN, Shehata MK, El-Gamal R. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells. Eur J Med Chem 2021;210:113081. [PMID: 33310290 DOI: 10.1016/j.ejmech.2020.113081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Nishida N, Kudo M. Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1274. [PMID: 32443599 DOI: 10.3390/cancers12051274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
18 Abdel-Mohsen HT, Abdullaziz MA, Kerdawy AME, Ragab FAF, Flanagan KJ, Mahmoud AEE, Ali MM, Diwani HIE, Senge MO. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles. Molecules 2020;25:E770. [PMID: 32053964 DOI: 10.3390/molecules25040770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
19 Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022;10:3. [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
20 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
21 Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel) 2020;12:E1668. [PMID: 32585931 DOI: 10.3390/cancers12061668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
22 Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol 2020;10:601240. [PMID: 33585218 DOI: 10.3389/fonc.2020.601240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 Vizio B, Bosco O, David E, Caviglia GP, Abate ML, Schiavello M, Pucci A, Smedile A, Paraluppi G, Romagnoli R, Lupia E, Bellone G, Montrucchio G. Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma. Int J Mol Sci 2021;22:1818. [PMID: 33673041 DOI: 10.3390/ijms22041818] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Sannappa Gowda NG, Shiragannavar VD, Prabhuswamimath SC, Tuladhar S, Chidambaram SB, Santhekadur PK. Ehrlich Ascites carcinoma mice model for studying liver inflammation and fibrosis. Advances in Cancer Biology - Metastasis 2022;4:100029. [DOI: 10.1016/j.adcanc.2022.100029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]